Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enanta Pharmaceuticals, Inc. - Common Stock (NQ: ENTA )

7.140 -0.360 (-4.80%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 419,302
Open 7.500
Bid (Size) 7.160 (2)
Ask (Size) 8.260 (2)
Prev. Close 7.500
Today's Range 7.080 - 7.680
52wk Range 4.710 - 17.80
Shares Outstanding 21,055,392
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Thursday's session: gap up and gap down stocks
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
The Analyst Verdict: Enanta Pharma In The Eyes Of 4 Experts
Via Benzinga

Performance

YTD
+27.73%
+27.73%
1 Month
+47.22%
+47.22%
3 Month
-25.39%
-25.39%
6 Month
-43.47%
-43.47%
1 Year
-45.03%
-45.03%

More News

Read More
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharma Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
4 Analysts Assess Enanta Pharma: What You Need To Know
Via Benzinga
United Airlines To Rally More Than 20%? Here Are Top Analyst Forecasts For Monday
Via Benzinga
CrowdStrike To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharma Earnings Analysis: Q4 Recap
Via Benzinga
Enanta Pharma Q4 Earnings Assessment
Via Benzinga
Insights into Enanta Pharma Q4 Earnings
Via Benzinga
Enanta Pharma: Q4 Earnings Insights
Via Benzinga
Earnings Breakdown: Enanta Pharma Q4
Via Benzinga
Enanta Pharma's Earnings Outlook
Via Benzinga
A Glimpse Into The Expert Outlook On Enanta Pharma Through 4 Analysts
Via Benzinga
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For November 25, 2024
Via Benzinga
Enanta Pharmaceuticals Reports Antiviral For Respiratory Syncytial Virus Reduces Virus Levels, Symptoms In Study
Via Benzinga
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Participate in Investor Conferences in September
From Enanta Pharmaceuticals, Inc.
Via Business Wire
ENTA Stock Earnings: Enanta Pharma Beats EPS, Beats Revenue for Q3 2024
Via InvestorPlace
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.